Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Kansas City, MO, March 26, 2021 (GLOBE NEWSWIRE) -- Northern Genesis Acquisition Corp. III (the “Company”) announced today that it closed its initial public offering of 15,000,000 units at $10.00...
-
BUFFALO, N.Y., March 26, 2021 (GLOBE NEWSWIRE) -- ACV Auctions Inc. (“ACV”), the leading online automotive marketplace for dealers, today announced the closing of its initial public offering of...
-
CARLSBAD, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc., a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of...
-
SHANGHAI, China, March 26, 2021 (GLOBE NEWSWIRE) -- Hywin Holdings Ltd. (“Hywin” or the “Company”) (NASDAQ: HYW), the third largest third-party wealth management service provider in China, today...
-
ORANGE, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”), a mission-based, tech-enabled Medicare Advantage company, today announced the...
-
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Newbury Street Acquisition Corporation (the “Company”) announced today the closing of its initial public offering of 12,000,000 units at a price of...
-
BETHESDA, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public offering of 3,636,364 shares of its common stock and full...
-
TORONTO, March 25, 2021 (GLOBE NEWSWIRE) -- Goodman & Company, Investment Counsel Inc. (the “Manager”) is pleased to announce that CMP 2021 Resource Limited Partnership (the “Partnership”) has...
-
UTRECHT, The Netherlands, March 25, 2021 (GLOBE NEWSWIRE) -- Gilde Healthcare, a specialized healthcare investor with $1.8 billion under management, today announced that its portfolio company, LAVA...
-
荷兰乌得勒支和美国费城, March 25, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics B.V.（纳斯达克股票代码：LVTX），一家专注于使用其在双特异性gamma-delta T细胞衔接蛋白抗体构建体方面的专业知识来转变癌症疗法的生物科技公司，今天宣布其首次公开发行的6,7000,000股普通股定价为每股15美元。此外，LAVA...